

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 November 2008 (27.11.2008)

PCT

(10) International Publication Number
WO 2008/144738 A1

- (51) International Patent Classification:
A61K 33/10 (2006.01) A61P 23/02 (2006.01)
A61K 45/06 (2006.01)
- (21) International Application Number:
PCT/US2008/064381
- (22) International Filing Date: 21 May 2008 (21.05.2008)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/939,540 22 May 2007 (22.05.2007) US
- (71) Applicant and
(72) Inventor: ABRAHMSOHN, Glenn [US/US]; 795 Harbor Drive, Key Biscayne, FL 33149 (US).
- (74) Agent: BEDGOOD, Robert, M.; Pillsbury Winthrop Shaw Pittman, LLP, P.O.Box 10500, McLean, VA 22102 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,


AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:
— of inventorship (Rule 4.17(iv))

Published:
— with international search report

(54) Title: METHOD FOR PAIN CONTROL



(57) Abstract: Methods for providing post-operative pain control or relief to a patient are disclosed. Methods include, for example, administering bicarbonate to an area of a patient during a surgical or dental procedure, near completion of a surgical or dental procedure or immediately following a surgical or dental procedure, in an area previously administered or containing a regional or local anesthetic in an amount sufficient to provide the patient with pain control or relief for a period of time after the surgical or dental procedure.



WO 2008/144738 A1

METHOD FOR PAIN CONTROL

RELATED APPLICATIONS

This application claims priority to U.S. provisional application
5 60/939,540, filed May 22, 2007, which is expressly incorporated herein by
reference.

INTRODUCTION

Anesthetic agents are pharmacologically active agents that block nerve
conduction when applied in therapeutically effective amounts. Anesthetics can
10 be used for local, regional or systemic application. Anesthetics may be applied
by injection, ointments, jellies, pastes, topical solutions and suspensions or
other forms.

SUMMARY OF THE INVENTION

The invention is based in part on a regional or local anesthesia that can
15 be converted to extend or provide pain (chronic or acute) control or relief.
Administration of an inorganic or organic salt agent, such as a bicarbonate
(*e.g.*, sodium bicarbonate, 4.8%, pH 7.8-8.2), a buffered phosphated nitrated
salt, to a patient that has previously been administered a regional or local
anesthesia alters the regional or local anesthesia so as to provide or extend
20 pain (chronic or acute) control in the patient.

The invention therefore provides methods for providing or extending
pain (chronic or acute) control or relief to a patient. In one embodiment, a
method includes administering an inorganic or organic salt agent (*e.g.*,
bicarbonate) to an area of a patient, wherein the area has previously been
25 administered or contains a regional or local anesthetic, and wherein the
amount of inorganic or organic salt agent (*e.g.*, bicarbonate) administered is
sufficient to provide the patient with pain (chronic or acute) control or relief
for a period of time. In another embodiment, a method includes administering
a regional or local anesthetic to the patient; and administering an inorganic or
30 organic salt agent (*e.g.*, bicarbonate) to an area of the patient that contains the
regional or local anesthetic, and wherein the amount of inorganic or organic
salt agent (*e.g.*, bicarbonate) administered is sufficient to provide the patient
with pain (chronic or acute) control or relief for a period of time. In an

additional embodiment, a method includes administering a regional or local anesthetic to the patient during a surgical or dental procedure, near completion of a surgical or dental procedure or immediately following a surgical or dental procedure; and administering an inorganic or organic salt agent (*e.g.*,
5 bicarbonate) into the area of the patient administered the regional or local anesthetic, wherein the amount of inorganic or organic salt agent (*e.g.*, bicarbonate) administered is sufficient to provide the patient with pain (chronic or acute) control or relief for a period of time after the surgical or dental procedure. In a further embodiment, a method includes administering a
10 regional or local anesthetic to a patient during a surgical or dental procedure, near completion of a surgical or dental procedure or following a surgical or dental procedure; and administering an inorganic or organic salt agent (*e.g.*, bicarbonate) into the area of the patient administered the regional or local anesthetic, wherein the amount of inorganic or organic salt agent (*e.g.*,
15 bicarbonate) administered is sufficient to extend pain (chronic or acute) control or relief to the patient for a period of time.

The methods of the invention include methods that provide or extend pre- or post-operative pain (chronic or acute) control. Thus, for example, in various aspects of the invention, an inorganic or organic salt agent (*e.g.*,
20 bicarbonate) such as a bicarbonate (*e.g.*, sodium bicarbonate, 4.8%, pH 7.8-8.2) or buffered phosphated nitrated salt, is administered to a patient in need of pain control or extension of pain control that has been administered a regional or local anesthetic. The methods of the invention may also be practiced during a surgical or dental procedure, near completion of a surgical or dental
25 procedure or immediately following a surgical or dental procedure. Thus, for example, in various aspects of the invention, a patient is provided with or extended pain (chronic or acute) control during a surgical or dental procedure or following a surgical or dental procedure by appropriate administration of an inorganic or organic salt agent (*e.g.*, bicarbonate).

30

DESCRIPTION OF DRAWING

Figure 1 shows a schematic diagram of a proposed mechanism.

DETAILED DESCRIPTION OF THE INVENTION

The invention methods provide or extend pain control or relief of regional and local anesthetics. The term “anesthetic” or “anesthesia” used herein refers to a substance that inhibits, reduces, prevents or blocks pain
5 sensation.

A “regional” or “local” anesthetic means an anesthetic having an effect limited to a given area or a part of the body of a patient that remains conscious, as opposed to a general anesthesia where a subject loses consciousness- although a patient may be sedated to relax the patient. A
10 regional anesthetic affects a large part of the body. A local anesthetic affects a smaller or specific part of the body.

Regional anesthesia generally involves the administration of anesthetics to block the nerve supply to a specific part of the body, such as a limb (*e.g.*, leg, arm, lower part of the body, etc.), so a patient does not feel
15 pain in that specific part of the body, but retains sensation in other parts of the body. Specific non-limiting examples of regional anesthetics include epidural anesthesia, spinal anesthesia, brachial plexus blocks, and intravenous regional techniques (*e.g.*, Bier blocks). Regional anesthesia further include nerve blocks that affect major peripheral nerves such as femoral and sciatic nerves.

20 Local anesthesia generally involves administration of anesthesia to block peripheral nerves at the region or area in which is it desired to suppress pain. A local anesthetic is typically administered by injection or applied to a body surface (*e.g.*, topically via a liquid, paste, ointment, jelly or cream), and then diffuses into nerves where it inhibits the propagation of one or more of
25 pain, muscle contraction, regulation of blood circulation and other body functions. Relatively high doses or concentrations of anesthesia inhibit all sensation (pain, touch, temperature, etc.) as well as muscle control. Lower doses or concentrations of anesthetic can inhibit pain sensation while minimizing the effect on muscle control.

30 Anesthesia administered regionally or locally therefore includes, among others, surface anesthesia, infiltration, field block anesthesia, nerve block anesthesia, intravenous regional anesthesia, spinal anesthesia and

epidural anesthesia. Surface anesthesia involves topical administration to the skin or mucous membranes such as those found in the nose, mouth, throat, tracheo-bronchial tree, esophagus and the genitourinary tract. Infiltration anesthesia typically is an injection of anesthetic directly into the desired tissue.

5 This anesthesia can be superficial so as to include only the skin or include deeper structures including intra-abdominal organs. Infiltration or other anesthetic techniques permit effective anesthesia delivery without disruption of normal body functions. Field block regional anesthesia typically is a subcutaneous injection of local anesthetic to interrupt nerve transmission

10 proximal to the site to be anesthetized. Nerve block regional anesthesia typically involves injection of anesthetic into or about individual or peripheral nerves or nerve plexus thereby affecting larger areas. Intravenous regional anesthesia typically involves injection into a vein of an extremity previously exsanguinated and kept exsanguinated. Spinal anesthesia typically involves

15 injection of anesthetic into the lumbar subarachnoid space. Epidural anesthesia typically involves injection of anesthetic into the epidural space.

Regional and local anesthetics useful in practicing the methods of the invention include a large number of compounds. Specific non-limiting examples of regional and local anesthetics include editocaine, hexylcaine,

20 iontocaine, decicaine, dibucaine, dyclonine, pramoxine, proparacaine and oxybuprocaine (Benoxinate). Anesthetics include amino amides and opiates/opioids. Specific non-limiting examples of amino amide anesthetics include bupivacaine (Marcaine), levobupivacaine, lidocaine, lidocaine derivatives (e.g., N-(2,6-Dimethylphenylcarbamoymethyl) triethylammonium

25 bromide, also referred to as QX-314, a quaternary derivative of lidocaine, 2-(trimethylamino)-N-(2,6-dimethylphenyl)acetamide also referred to as QX-222, and N-beta-phenylethyl lidocaine quaternary ammonium bromide), mepivacaine, prilocaine, ropivacaine, articaine (Septocaine) and trimecaine. Prilocaine and articaine (Septocaine) have thiol rings. Specific non-limiting

30 examples of opiates/opioids include fentanyl and morphine. Anesthetics include esters or amides of benzylic acid derivatives, such as benzocaine, chlorprocaine, cocaine, tetracain (Pontocaine) and procaine (Novocaine). Anesthetics include prodrugs.

Anesthetics can be in a hydrochloride acid-addition salt. Typically, regional or local anesthetics are administered in a solution (*e.g.*, aqueous solution), for example, a form of hydrochloride acid-addition salt in an aqueous solution.

5 Doses can be based upon current existing treatment protocols, empirically determined, determined using animal disease models or in human clinical studies. For example, a regional or local anesthetic is typically administered in a solution from about 0.5 to 5% and in other mixtures of up to 20% or 30% or more by weight/volume. The amount administered depends
10 on the route or area for administration. For application to an oral cavity (*e.g.*, mouth or buccal tissue), the amount administered generally is no more than 6 ml of a 2% solution.

 Typical amounts of lidocaine that are commercially available as the hydrochloride and is used in preparations in about 0.5 to about 20% by weight,
15 volume (up to about 7 mg/kg body weight), some with and some without epinephrine for infiltration, about 1 to 2% for block and about 5% for topical mucosal anesthesia. Bupivacaine is used commercially as a hydrochloride in solutions from about 0.25 to about 0.75%; chloroprocaine, typically as the hydrochloride in solutions of about 1 to 3%. Epiocaine is typically used as a
20 hydrochloride in solutions of about 1 to 2%. Mepivacaine is typically used in solutions of from about 1 to 3%, optionally with or without levonordenphedrine as a vasoconstrictor. Prilocaine is typically used as the hydrochloride in solution at about 4%, optionally with or without epinephrine as a vasoconstrictor. Procaine is typically used as the hydrochloride in
25 solutions of about 0.25 to 0.5% for infiltration, 0.5% to 2% for peripheral nerve block and 10% for spinal anesthesia. Tetracaine is typically used in solutions as the hydrochloride of about 5% as an ointment and about 2% for application to the mucous membranes or throat. Tetracaine for injection is available in solutions or ampules containing the dry salt, as well as ointments
30 of 5% and creams of 1%.

 After a regional or local anesthesia has been administered to the patient, inorganic or organic salt agent is administered. Although not wishing to be bound by any theory, it is believed that a regional or local anesthesia is

converted by an inorganic or organic salt agent to an anesthetic which provides or extends pain control or relief (Figure 1). For example, a bicarbonate can attach to an amide or thiol ring thereby extending anesthetic action or activity. Thus, the inorganic or organic salt agent alters or
5 transforms the regional or local anesthesia into a slow or prolonged release form that functions as a prolonged regional or local anesthetic, thereby providing or extending pain control or relief. Typically, inorganic or organic salt agent that is administered to a patient does not also contain an anesthetic, i.e., is not a mixture of inorganic or organic salt agent and a regional or local
10 anesthetic.

The area or site of inorganic or organic salt agent administration will therefore have some amount of regional or local anesthesia. Thus, the site of administration is typically in relative close proximity to, or within, the area that has previously been administered a regional or local anesthesia or that
15 otherwise contains some amount (*e.g.*, by diffusion, by transport through patient circulation, etc.) of regional or local anesthesia. Specific non-limiting examples of areas of a patient that are appropriate for administration of a regional or local anesthesia and inorganic or organic salt agent include a wound or cut, a surgical (*e.g.*, incision site or area) or dental area (*e.g.*,
20 extracted tooth site or area) or region, torso, stomach, chest, head, scalp, neck, face, nose, ear, shoulder, back, arm, leg, thigh, ankle, knee, foot, toe, hand, wrist, finger, buttocks, groin, and joints. Accordingly, administration of regional or local anesthesia, or an inorganic or organic salt agent, can be to or near a wound or cut, a surgical or dental region such as to an incision or site of
25 a surgical or dental procedure (*e.g.*, extracted tooth site), or any other affected area, tissue, organ of the body (*e.g.*, torso, stomach, chest, head, scalp, neck, face, nose, ear, shoulder, back, arm, leg, thigh, ankle, knee, foot, toe, hand, wrist, finger, buttocks, groin, and joints).

The term "inorganic or organic salt agent" refers to a salt. Such salts
30 include those capable of being adjusted to a pH of about 7 or greater. A salt is typically an alkali or alkaline earth metal salt of an inorganic or organic acid, such as a salt of a weak acid, and strong base, or weak base. In order to

achieve a pH of about 7 or greater, a salt is typically a salt of a weak acid and strong base, or of a salt of a weak acid and a weak base.

Typical cations of the salt are sodium, potassium, calcium and magnesium. Typical anions are monovalent inorganic anions such as fluoride, bromide and chloride; multivalent organic anions such as carbonate, hydrogen carbonate; and multivalent inorganic anions such as sulphate, and phosphate. Non-toxic inorganic anions of organic acids include anions of mono-like and dibasic organic acids such as acetate, gluconate and mono- or di-carboxylic acids.

10 Exemplary specific examples to administer to a subject that has been previously administered or that contains a regional or local anesthetic in order to provide or extend pain control or relief include bicarbonates (*e.g.*, sodium bicarbonate, 4.8%, pH 7.8-8.2, such as with carbon dioxide), and buffered phosphated nitrated salts.

15 Amounts of inorganic or organic salt agents to administer to a subject. Amounts of inorganic or organic salt agent salt administered are in a 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1 10:1 ratio to the regional or local anesthetic administered. Typical amounts of inorganic or organic salt agent salt administered is in a 1:1 ratio to the regional or local anesthetic administered.

20 Typical amounts of inorganic or organic salt agent salt (*e.g.*, bicarbonate) administered are from about 1% to 15%, or about 2 to 10% or about 4 to 10%. Typically, the salt is present, depending upon solubility, in an amount of approximately 1 molar in aqueous solution. In the case of sodium bicarbonate, a 1 molar, or meq/ml (84 mgs/ml) solution has a pH of about 7.8-8.2. Such a

25 solution can be conveniently contained in dosage unit of a size of approximately 1.8 ml for application to oral cavity, for example.

A "sufficient" or "effective" amount as used herein means an amounts that achieves or is likely to achieve a desired effect or outcome. Thus, in a method of the invention a sufficient or effective amount will provide or extend

30 pain control or relief in a given patient to a measurable or detectable extent. In particular embodiments, pain control or relief provided to the patient has a

duration of about 0.5-72 hrs, about 0.5-48 hrs, about 0.5-24 hrs, or about 1-12 hrs.

Sufficient or effective amounts depend upon the desired effect, the anesthetic administered to the patient, the inorganic or organic salt agent administered that provides or extends pain control or relief to the patient, the location of administration and the form administered. Of course, as is typical for any treatment or therapy, different patients will exhibit different responses to treatment and some patients may not respond or respond inadequately to a particular treatment. Since every treated patient may not respond to a particular method, the methods set forth herein are not required to achieve pain control or relief in each and every patient, or a given population so treated. Accordingly, an amount sufficient or an amount effective means sufficiency or effectiveness in a particular patient, not a group of subjects or the general population.

Administration of regional or local anesthetic, or inorganic or organic salt agent, in accordance with the invention methods include any mode (*e.g.*, bolus dose or a slow or delayed release) or route of administration or delivery. Exemplary delivery and administration routes include oral (buccal, sublingual, alimentary, mucosal), intravenous, intrarterial, intradermal, parenteral (*e.g.*, subcutaneous, intramuscular), intra-tumor, intra-pleural, topical (dermal), transdermal, transmucosal, intra-cranial, intra-spinal, intra-tracheal, epidural, intra-ocular, intracavity, iontophoretic, rectal, vaginal, intrauterine, ophthalmic, optical (*e.g.*, corneal), intraglandular, intraorgan, intralymphatic, intrapulmonary, intranasal and intrathecal.

Typically, an inorganic or organic salt agent will be administered in a fluid (*e.g.*, aqueous or non-aqueous solution) having a pH equal to or greater than about pH 7, for example between about pH 7-11 and more typically between about pH 7 to 8.5 (*e.g.*, 7.8-8.2, such as with carbon dioxide). There is no upper limit to the pH. In practice, upper limit of pH is determined by the nature of the salt, any buffer or base present, and the concentration of inorganic or organic salt agent. Additionally, skin sensitivity to basic substances is such that a pH typically not greater than 10 and more typically not greater than 9 is used.

A desired pH can be maintained in a buffer. For example, a buffer can maintain a pH of about 7 or more, or a pH of at least 7.8, or a pH from about 7 to 8.5. Typical buffers include inorganic and organic buffers including phosphate, citrate, bicarbonate and the like. The upper limit of the pH is not limited except that, the upper limit of the pH can be affected by the nature of the salt, and any buffer, and concentration of base that may be used to adjust the pH. A desired pH can be obtained using carbon dioxide, for example.

A regional or local anesthetic, or inorganic or organic salt agent, can be administered in a non-toxic pyrogen free, fluid mixture. The term "non-toxic" used herein means not causing death of a patient or undesirable side effects, such as permanent damage to a nerve or muscle. Systemic toxicity of agents and anesthetics administered in accordance with the invention are optionally low. The term "pyrogen free" when applied to regional or local anesthetic, or inorganic or organic salt agent suitable for administration to a patient means that the anesthetics and agents do not contain substances known to cause a pyrogenic response. Pyrogens can be removed from mixtures by methods known to one skilled in the art.

Administration of regional or local anesthetic or inorganic or organic salt agent in accordance with the invention methods can be performed multiple times (*e.g.*, 1-10, 1-5 or 1-3 times) per minute, hour, day, week or month. For example, in various embodiments of the invention, an inorganic or organic salt agent is administered to a patient immediately following administration of regional or local anesthetic. In various additional embodiments of the methods of the invention, an inorganic or organic salt agent is administered to a patient within about 1-5, 1-10, 2-10, 5-20, 15-30, 30-60 or 60-120 minutes after administration of regional or local anesthetic.

The method can optionally be used in conjunction with a vasoconstrictor to prolong the duration of the action. For example, an anesthetic can be administered concomitantly with a vasoconstrictor. The term "vasoconstrictor" used here means an agent capable of causing constriction of blood vessels including various sympathomimetic drugs such as epinephrine, norepinephrine, levonordenphedrine and dopamine. Typically,

epinephrine is administered in a dilution of 1:100,000 mixed with a solution of lidocaine and supplied in 1.8 ml capsules.

The invention methods are appropriate in any surgical or dental procedure or context in which a local or regional anesthetic is used or has
5 already been administered to a patient. Non-limiting examples of surgical and dental procedures include cancer or tumor surgery, trauma surgery, cosmetic surgery, abdominal surgery, head or neck surgery, orthopedic surgery, back or spine surgery, arthroscopic surgery, brain surgery, ear, nose or throat surgery, eye surgery, amputation, liposuction, rhinoplasty, graft or transplant surgery, a
10 biopsy, skin surgery, breast surgery, prosthetic surgery, fetal surgery, gastroenterologic surgery, thoracic surgery, bladder surgery, heart surgery, liver surgery, pancreas surgery, kidney surgery, lung surgery, gallstone surgery, hernia surgery, shoulder, arm, leg, pelvis, hip, knee, elbow or ankle surgery, uterine or vaginal surgery, blood vessel surgery, prostate surgery,
15 colon or rectal surgery, laser surgery, oral surgery, periodontal surgery, dental implant or tooth repair or extraction.

The invention methods can employ pharmaceutical compositions and formulations. As used herein the terms “pharmaceutically acceptable” and “physiologically acceptable” mean a biologically compatible formulation,
20 gaseous, liquid or solid, or mixture thereof, which is suitable for one or more routes of administration, *in vivo* delivery or contact. A formulation is compatible in that it does not destroy activity of an active ingredient therein, or induce adverse side effects that far outweigh any therapeutic benefit or effect.

25 Such formulations include solvents (aqueous or non-aqueous), solutions (aqueous or non-aqueous), emulsions (*e.g.*, oil-in-water or water-in-oil), suspensions, syrups, elixirs, dispersion and suspension media, coatings, isotonic and absorption promoting or delaying agents, compatible with pharmaceutical administration or *in vivo* contact or delivery. Aqueous and
30 non-aqueous solvents, solutions and suspensions may include suspending agents and thickening agents.

Cosolvents may be added. Non-limiting examples of cosolvents contain hydroxyl groups or other polar groups, for example, alcohols, such as isopropyl alcohol; glycols, such as propylene glycol, polyethyleneglycol, polypropylene glycol, glycol ether; glycerol; polyoxyethylene alcohols and polyoxyethylene fatty acid esters.

Supplementary active compounds (*e.g.*, preservatives, antioxidants, antimicrobial agents including biocides and biostats such as antibacterial, antiviral and antifungal agents) can also be incorporated. Preservatives and other additives include, for example, antimicrobials, anti-oxidants, chelating agents and inert gases (*e.g.*, nitrogen).

Preservatives include, for example, EDTA, EGTA, benzalkonium chloride or benzoic acid or benzoates, such as sodium benzoate. Antioxidants include, for example, ascorbic acid, vitamin A, vitamin E, tocopherols, and similar vitamins or provitamins. Antimicrobials include, antibacterial, antiviral, antifungal and antiparasitics that kill or destroy (-cidal) or inhibit (-static) contamination by or growth, infectivity, replication, proliferation, reproduction of the microbial organism.

Pharmaceutical compositions can optionally be formulated to be compatible with a particular route of administration. Thus, pharmaceutical compositions include carriers (excipients, diluents, vehicles or filling agents) suitable for administration by various routes and delivery, regionally, locally or systemically, *ex vivo* or *in vivo*, as set forth herein or known to the skilled artisan.

Formulations suitable for parenteral administration include aqueous and non-aqueous solutions, suspensions or emulsions of the compound, which may include suspending agents and thickening agents, which preparations are typically sterile and can be isotonic with the blood of the intended recipient. Non-limiting illustrative examples of aqueous carriers include water, saline (sodium chloride solution), dextrose (*e.g.*, Ringer's dextrose), lactated Ringer's, fructose, ethanol, animal, vegetable or synthetic oils. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate.

Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose).

For transmucosal or transdermal administration (*e.g.*, topical contact), penetrants can be included in the pharmaceutical composition. Penetrants
5 include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. For transdermal administration, the active ingredient can be formulated into aerosols, sprays, ointments, salves, gels, pastes, lotions, oils or creams.

For oral administration, pharmaceutical compositions include capsules,
10 cachets, lozenges, tablets or troches, as powder or granules. Oral administration formulations also include a solution or a suspension (*e.g.*, aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil emulsion).

For topical administration, for example, to skin, pharmaceutical
15 compositions typically include ointments, creams, lotions, pastes, gels, sprays, aerosols or oils. Carriers which may be used include Vaseline, lanolin, polyethylene glycols, alcohols, transdermal enhancers, and combinations thereof.

Additional pharmaceutical formulations appropriate for administration
20 are known in the art (see, *e.g.*, Gennaro (ed.), Remington: The Science and Practice of Pharmacy, 20th ed., Lippincott, Williams & Wilkins (2000); Ansel *et al.*, Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th ed., Lippincott Williams & Wilkins Publishers (1999); Kibbe (ed.), Handbook of Pharmaceutical Excipients American Pharmaceutical Association, 3rd ed.
25 (2000); and Remington's Pharmaceutical Principles of Solid Dosage Forms, Technomic Publishing Co., Inc., Lancaster, Pa., (1993)).

The term "patient" or "subject" are used interchangeably herein and refer to animals, typically mammals, such as humans, non-human primates (gorilla, chimpanzee, orangutan, macaque, gibbon), domestic animals (dog
30 and cat), farm and ranch animals (horse, cow, steer, goat, sheep, goat, pig), laboratory and experimental animals (mouse, rat, rabbit, guinea pig). Human subjects include children, for example, newborns, infants, toddlers and teens,

between the ages of 1 and 5, 5 and 10 and 10 and 18 years, adults between the ages of 18 and 60 years, and the elderly, for example, between the ages of 60 and 65, 65 and 70 and 70 and 100 years.

Patients and subjects include mammals (*e.g.*, humans) in need of
5 treatment, that is, for example, they are at risk of or are experiencing
undesirable pain. Such patients and subjects therefore include those that are
undergoing a surgical or dental procedure that results or is likely to result in
("at risk of") pain due to the surgical or dental procedure. Patients and
subjects can therefore be treated in order to inhibit or reduce the likelihood or
10 risk of developing pain. The result of such treatment can be to provide or
extend pain control to the patient or subject.

The invention further provides kits, including regional and local
anesthetics, and inorganic or organic salt agents, and pharmaceutical
formulations thereof, packaged into suitable packaging material, optionally in
15 combination with instructions for using the kit components, *e.g.*, instructions
for providing or extending pain control or relief. Invention kits can include
therein a individual container or in a mixture and all of the various containers
can be within single or multiple packages that comprise the kit.

The term "packaging material" refers to a physical structure housing
20 the components of the kit. The packaging material can maintain the
components sterilely, and can be made of material commonly used for such
purposes (*e.g.*, paper, corrugated fiber, glass, plastic, foil, ampules, etc.).

The label or packaging insert can include appropriate written
instructions. Thus, in various embodiments, a kit includes a label or
25 packaging insert including instructions for practicing a method of the
invention.

Instructions may additionally include indications of a satisfactory
clinical endpoint or any adverse symptoms or complications that may occur.
Instructions may further include storage information, expiration date, or any
30 information required by regulatory agencies such as the Food and Drug
Administration for use in a human subject.

The instructions may be on "printed matter," *e.g.*, on paper or cardboard within the kit, on a label affixed to the kit or packaging material, or attached to a vial or tube containing a component of the kit. Instructions may comprise audio or video medium and additionally be included on a computer
5 readable medium, such as a disk (floppy diskette or hard disk), optical CD such as CD- or DVD-ROM/RAM, magnetic tape, electrical storage media such as RAM and ROM and hybrids of these such as magnetic/optical storage media.

Unless otherwise defined, all technical and scientific terms used herein
10 have the same meaning as commonly understood by one of ordinary skill in the art to which this invention relates. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the invention, suitable methods and materials are described herein.

All publications, patents, and other references cited herein are
15 incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control.

As used herein, singular forms "a", "and," and "the" include plural referents unless the context clearly indicates otherwise. Thus, for example, reference to "an anesthetic" includes a plurality of anesthetics and reference to
20 "an inorganic or organic salt agent" can include multiple inorganic or organic salt agents, and so forth.

As used herein, reference to a numerical value or numerical range includes reference to a fraction of such values, and whole integers and fractions within or encompassing such ranges of the values or integers within
25 or encompassing ranges unless the context clearly indicates otherwise. Thus, for example, reference to a numerical value of 7 includes reference to 7.1, 7.2, and so forth. Reference to a range of 1-15%, includes 2, 3, 4, 5, 6, 7, 8%, etc., as well as 1.1, 1.2, 1.3, 1.4, 1.5%, etc., 2.1, 2.2, 2.3, 2.4, 2.5%, etc., and so forth. In another example, reference to a ratio of 2:1 includes 2:1.1, 2:1.2,
30 2:1.3, 2:1.4, 2.1:1, 2.2:1, 2.3:1, 2.4:1, and so forth.

The invention is generally disclosed herein using affirmative language to describe the numerous embodiments. The invention also specifically

includes embodiments in which particular subject matter is excluded, in full or in part, such as substances (*e.g.*, particular anesthetics or inorganic or organic salt agents) or materials, method steps and conditions, protocols, procedures, assays or analysis. Thus, even though the invention is generally not expressed
5 herein in terms of what the invention does not include, aspects that are not expressly included in the invention are nevertheless disclosed.

A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, the
10 following examples are intended to illustrate but not limit the scope of invention described in the claims.

EXAMPLES

**CONCENTRATION OF AMIDE
LOCAL ANESTHESIA**

SITE OF OPERATION	1.5% LIDOCAINE or EQUIVALENT	0.5% MARCAINE/ 0.5% BUPIVICAINE	PAIN CONTROL w/Buffered NaHCo3 4.2% - 8.4% use 3 times volume of NaHCo3
Upper abdominal	30 ml	30 ml	30 - 90 ml
Lower abdominal	20 ml	20 ml	20 - 60 ml
Hernias & varicose veins	20 ml	20 ml	20 - 60 ml
Perineal/bladder-neck Operations	15 ml	15 ml	15 - 45 ml
{ Cervical plexus blocks	1 % Lido 10-20 ml	10-20 ml 5 ml	10 - 60 ml} 5 - 15 ml}
{ 2nd block-cervical plexus	1.0-1.5% Lido 5ml		
{ 3rd & 4th cervical vertebrae			
Intercostal block	0.5-1% Lido 3- 4ml	3-4 ml	3 - 9 ml
Para verterbral somatic n.block	1 % Lido 5 ml	5 ml	5 -15 ml
Brachial plexus	1.2% 5-10ml @ ea Site total of 30- 40ml	5-10ml @ ea. site total of 30- 40ml	5 -15 ml max @ 90-120 ml
Interscalene brachial Plexus block	1-1.5% Lido 20-40ml	20-40ml	20 -120 ml
Superclavicular block	1-1.5% 20-25ml	20-25ml	20 - 75 ml
Nerve block @ elbow			
Median nerve	2% Lido 2-3m.	2-3ml	2 - 9 ml
Radial nerve	2% Lido 10ml	10ml	10 - 30 ml
Ulnar nerve	2% Lido 2ml	2ml	2 - 6 ml

	CONCENTRATION OF AMIDE LOCAL ANESTHETIC		AMOUNT OF BUFFERED NaHCo3
Nerve block @ wrist			
Medial nerve	2% Lido 1-2ml	1-2ml	1 - 6 ml
Ulnar nerve	2% Lido 2ml	2ml	2 - 6 ml
Radial nerve	2% Lido 2ml	2ml	2 - 6 ml
Hand & Digital blocks	avoid excessive distention		& no epi
	1% 5ml	5ml	5 ml
Femoral nerve block	1% Lido	5-10ml	5-30 ml
Lateral Femoral cutaneous Nerve block	1% Lido 5-10ml	5-10ml	5-30 ml
Sciatic nerve block	2% Lido 10-20ml	10-20ml	10 - 60 ml
Intravenous regional Anesthesia	see article		= to 3xvolume
Epidural anesthesia	1.5% 10ml	0.5% 10ml	10 - 30 ml
Continuous epidural Anesthesia	0.2% Bupivacaine @ rate of 2ml/hr for 48 hours	2ml/hr	2ml/hr
Spinal anesthesia	0.5% Amethocaine in 10% Glucose over 20 secs.	2ml	2ml-plus if needed

What is Claimed is:

1. A method for providing post-operative pain control or relief to a patient comprising administering bicarbonate to an area of a patient during a surgical or dental procedure, near completion of a surgical or dental procedure or immediately following a surgical or dental procedure, wherein the area has previously been administered or contains a regional or local anesthetic, and wherein the amount of bicarbonate administered is sufficient to provide the patient with pain control or relief for a period of time after the surgical or dental procedure.

2. A method for providing post-operative pain control or relief to a patient, comprising:

a) administering a regional or local anesthetic to the patient; and

b) administering bicarbonate to an area of the patient during a surgical or dental procedure, near completion of a surgical or dental procedure or immediately following a surgical or dental procedure,

wherein the area contains the regional or local anesthetic, and wherein the amount of bicarbonate administered is sufficient to provide the patient with pain control or relief for a period of time after the surgical or dental procedure.

3. A method for providing post-operative pain control or relief to a patient in need thereof during a surgical or dental procedure, near completion of a surgical or dental procedure or immediately following a surgical or dental procedure, comprising

a) administering a regional or local anesthetic to the patient during the surgical or dental procedure, near completion of the surgical or dental procedure or immediately following the surgical or dental procedure; and

b) administering bicarbonate into the area of the patient administered the regional or local anesthetic,

wherein the amount of bicarbonate administered is sufficient to provide the patient with pain control or relief for a period of time after the surgical or dental procedure.

4. A method for extending post-operative pain control or relief to a patient in need thereof, comprising

- a) administering a regional or local anesthetic to the patient during a surgical or dental procedure, near completion of a surgical or dental procedure or following a surgical or dental procedure; and
- b) administering bicarbonate into the area of the patient administered the regional or local anesthetic,

wherein the amount of bicarbonate administered is sufficient to extend pain control or relief to the patient for a period of time after the surgical or dental procedure.

5. The method of any of claims 1 to 4, wherein the bicarbonate administered does not contain an anesthetic.
6. The method of any of claims 1 to 4, wherein the bicarbonate converts the regional or local anesthetic into a slow or prolonged release regional or local anesthetic.
7. The method of any of claims 1 to 4, wherein the area of the patient comprises the torso, stomach, chest, head, scalp, neck, face, nose, ear, shoulder, back, arm, leg, thigh, ankle, knee, foot, toe, hand, wrist, finger, buttocks, groin, or a joint.
8. The method of any of claims 1 to 4, wherein the area of the patient comprises an incision or cut.
9. The method of any of claims 1 to 4, wherein the bicarbonate is administered to the patient immediately following the surgical or dental procedure, thereby providing or extending post-operative pain control or relief to the patient.
10. The method of any of claims 1 to 4, wherein the bicarbonate is administered multiple times.
11. The method of any of claims 1 to 4, wherein the regional or local anesthetic is administered topically, intradermally, intramuscularly, intravenously, subcutaneously, epidurally, by infusion or by injection.
12. The method of any of claims 1 to 4, wherein the bicarbonate is administered topically, intradermally, intramuscularly, intravenously, subcutaneously, epidurally, by infusion or by injection.
13. The method of any of claims 1 to 4, wherein the amount of bicarbonate administered is in a 1:1 ratio to the regional or local anesthetic administered.

14. The method of any of claims 1 to 4, wherein the amount of bicarbonate administered is in a 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1 10:1 or greater ratio to the regional or local anesthetic administered.

15. The method of any of claims 1 to 4, wherein the regional or local anesthetic comprises an opiate, an amide or an amine.

16. The method of any of claims 1 to 4, wherein the regional or local anesthetic comprises a prodrug.

17. The method of any of claims 1 to 4, wherein the regional or local anesthetic comprises editocaine, hexylcaine, iontocaine, decicaine, dibucaine, dyclonine, pramoxine, proparacaine, oxybuprocaine (Benoxinate), bupivacaine (Marcaine), levobupivacaine, lidocaine, a lidocaine derivative, mepivacaine, prilocaine, ropivacaine, articaine (Septocaine), trimecaine, fentanyl, morphine, benzocaine, chlorprocaine, cocaine, tetracain (Pontocaine) and procaine (Novocaine).

18. The method of claim 17, wherein the lidocaine derivative comprises QX-314, QX-222, or N-beta-phenylethyl lidocaine quaternary ammonium bromide.

The method of any of claims 1 to 4, wherein the bicarbonate comprises sodium bicarbonate.

19. The method of any of claims 1 to 4, wherein the sodium bicarbonate solution has a pH of greater than about 7.0.

20. The method of any of claims 1 to 4, wherein the sodium bicarbonate solution has a pH of about 7.0-11.0.

21. The method of any of claims 1 to 4, wherein the sodium bicarbonate solution has a pH of about 7.8-8.2.

22. The method of any of claims 1 to 4, wherein the bicarbonate comprises a solution of about 1 to 15% sodium bicarbonate.

23. The method of any of claims 1 to 4, wherein the bicarbonate comprises a solution of about 2 to 10% sodium bicarbonate.

24. The method of any of claims 1 to 4, wherein the bicarbonate comprises a solution of about 4 to 10% sodium bicarbonate.

25. The method of any of claims 1 to 4, wherein the bicarbonate comprises a solution of sodium bicarbonate, 4.8%, pH 7.8-8.2.

26. The method of any of claims 1 to 4, wherein the pain control or relief provided to the patient following administering bicarbonate has a duration of about 0.5-72 hrs, about 0.5-48 hrs, about 0.5-24 hrs, or about 1-12 hrs.

27. The method of any of claims 1 to 4, wherein the surgical or dental procedure comprises cancer or tumor surgery, trauma surgery, cosmetic surgery, abdominal surgery, head or neck surgery, orthopedic surgery, back or spine surgery, arthroscopic surgery, brain surgery, ear, nose or throat surgery, eye surgery, amputation, liposuction, rhinoplasty, graft or transplant surgery, a biopsy, skin surgery, breast surgery, prosthetic surgery, fetal surgery, gastroenterologic surgery, thoracic surgery, bladder surgery, heart surgery, liver surgery, pancreas surgery, kidney surgery, lung surgery, gallstone surgery, hernia surgery, shoulder, arm, leg, pelvis, hip, knee, elbow or ankle surgery, uterine or vaginal surgery, blood vessel surgery, prostate surgery, colon or rectal surgery, laser surgery, oral surgery, periodontal surgery, dental implant or tooth repair or extraction.


28. The method of any of claims 1 to 4, wherein the patient is a mammal.

29. The method of any of claims 1 to 4, wherein the patient is a primate.

30. The method of any of claims 1 to 4, wherein the patient is a human.

31. The method of any of claims 1 to 4, wherein the patient is a dog, cat, horse, cow, goat, steer or pig.

Fig. 1



INTERNATIONAL SEARCH REPORT

International application No
PCT/US2008/064381

A. CLASSIFICATION OF SUBJECT MATTER INV. A61K33/10 A61K45/06 A61P23/02				
According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED				
Minimum documentation searched (classification system followed by classification symbols) A61K				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, BIOSIS, COMPENDEX, EMBASE, MEDLINE				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
X	US 5 209 724 A (DHALIWAL AVTAR S [US] ET AL) 11 May 1993 (1993-05-11) column 15, line 48 - line 61; claim 1 -----	1-31		
X	CARVALHO ET AL: "Local infiltration of epinephrine-containing lidocaine with bicarbonate reduces superficial bleeding and pain during labor epidural catheter insertion: a randomized trial" INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA, CHURCHILL LIVINGSTONE, EDINBURGH, GB, vol. 16, no. 2, 15 March 2007 (2007-03-15), pages 116-121, XP005923693 ISSN: 0959-289X page 119; table 3 ----- -/--	1-31		
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none;"> <input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. </td> <td style="width: 50%; border: none;"> <input checked="" type="checkbox"/> See patent family annex. </td> </tr> </table>			<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C.	<input checked="" type="checkbox"/> See patent family annex.
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C.	<input checked="" type="checkbox"/> See patent family annex.			
* Special categories of cited documents :				
A document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family			
Date of the actual completion of the international search <p style="text-align: center; font-size: 1.2em;">22 July 2008</p>	Date of mailing of the international search report <p style="text-align: center; font-size: 1.2em;">29/07/2008</p>			
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer <p style="text-align: center; font-size: 1.2em;">Bochelen, Damien</p>			

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2008/064381

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5 693 312 A (STROPPOLO FEDERICO [CH] ET AL) 2 December 1997 (1997-12-02) example 17 -----	1-31
Y	WONG ET AL: "On the mechanisms of potentiation of local anesthetics by bicarbonate buffer: drug structure-activity studies on isolated peripheral nerve" ANESTHESIA AND ANALGESIA, WILLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 76, no. 1, 1 January 1993 (1993-01-01), pages 131-143, XP002093769 ISSN: 0003-2999 page 139; table 4 -----	1-31
Y	WO 93/00932 A (ABRAHMSOHN GLENN M [US]) 21 January 1993 (1993-01-21) page 2, line 25 - page 3, line 9; examples 1,2 -----	1-31

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2008/064381

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 1-31 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compositions.
2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers allsearchable claims.
2. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No PCT/US2008/064381
--

Patent document cited in search report	A	Publication date	Patent family member(s)	Publication date
US 5209724	A	11-05-1993	NONE	
US 5693312	A	02-12-1997	NONE	
WO 9300932	A	21-01-1993	AT 200627 T	15-05-2001
			AU 658347 B2	06-04-1995
			AU 2294892 A	11-02-1993
			DE 69231792 D1	23-05-2001
			DE 69231792 T2	15-11-2001
			DK 546160 T3	30-07-2001
			EP 0546160 A1	16-06-1993
			ES 2157904 T3	01-09-2001
			GR 3036219 T3	31-10-2001
			JP 6503099 T	07-04-1994
			JP 3578455 B2	20-10-2004
			US 5192527 A	09-03-1993